Cargando…

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grützmacher, P., Öhm, B., Szymczak, S., Dorbath, C., Brzoska, M., Kleinert, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352782/ https://www.ncbi.nlm.nih.gov/pubmed/28233269 http://dx.doi.org/10.1007/s11789-017-0090-3

Ejemplares similares

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias
por: Grützmacher, P., et al.
Publicado: (2015)

Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia
por: Nakamura, Yoshihiro, et al.
Publicado: (2021)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
por: Klingel, Reinhard, et al.
Publicado: (2017)

Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate
por: Cicero, Arrigo F.G., et al.
Publicado: (2013)

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)

Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
por: Ilina, Larisa N., et al.
Publicado: (2022)

Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
por: Fras, Zlatko
Publicado: (2020)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

A rare case of COVID-19 pneumonia with severe hyperlipoproteinemia
por: Shimoda, Masafumi, et al.
Publicado: (2022)

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment
por: Mangeshkar, Shaunak, et al.
Publicado: (2023)

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)
por: Pallazola, Vincent A., et al.
Publicado: (2019)

SUN-056 Recurrent Pancreatitis Induced by Uncontrolled Type V Hyperlipoproteinemia
por: Rivera Rivero, Bianshly, et al.
Publicado: (2019)

Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population
por: Xu, Jing, et al.
Publicado: (2020)

Management of Patients with Type V Hyperlipoproteinemia: An Uncommon Phenotype of Dyslipidemia with Chylomicronemia and Severe Hypertriglyceridemia
por: Chang, Ya-Hui, et al.
Publicado: (2022)

A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia
por: Hegele, Robert A., et al.
Publicado: (2009)

Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia
por: Georgiadou, Dimitra, et al.
Publicado: (2011)

Loss-of-Function Homozygous Variant in LPL Causes Type I Hyperlipoproteinemia and Renal Lipidosis
por: Wu, Hongyan, et al.
Publicado: (2023)

A Case of Hypothyroidism and Type 2 Diabetes Associated with Type V Hyperlipoproteinemia and Eruptive Xanthomas
por: Park, Jeong Rang, et al.
Publicado: (2005)

Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP)
por: Dildar, Shabnam, et al.
Publicado: (2020)

Recurrent Acute Pancreatitis in a Patient with Type IIb hyperlipoproteinemia: A Case Report and Review of the Literature in Korea
por: Kim, Byung Kook, et al.
Publicado: (2006)

Lipid apheresis techniques: current status in Germany
por: Grützmacher, Peter, et al.
Publicado: (2012)

Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy
por: Saleh, Mohannad Abou, et al.
Publicado: (2017)

Identification and Characterization of Two Novel Compounds: Heterozygous Variants of Lipoprotein Lipase in Two Pedigrees With Type I Hyperlipoproteinemia
por: Wang, Shuping, et al.
Publicado: (2022)

Cardiovascular disease risk and secondary prevention of cardiovascular disease among patients with low health literacy
por: van Schaik, T. M., et al.
Publicado: (2017)

Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated
por: Alves, Alberto J, et al.
Publicado: (2016)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

One more look at guidelines for primary and secondary prevention of cardiovascular disease in women
por: Kolovou, Genovefa, et al.
Publicado: (2011)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Smartphones in the secondary prevention of cardiovascular disease: a systematic review
por: Hamilton, Sandra J., et al.
Publicado: (2018)

Heartwatch: an Irish cardiovascular secondary prevention programme in primary care, a secondary analysis of patient outcomes
por: Homeniuk, Robyn, et al.
Publicado: (2023)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
por: Lopez-Lopez, Jose P, et al.
Publicado: (2023)

Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
por: van Zoest, Rosan A, et al.
Publicado: (2017)

Underutilization of Aspirin Persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease
por: Stafford, Randall S, et al.
Publicado: (2005)

Mediterranean-Style Diet for the Primary and Secondary Prevention of Cardiovascular Disease: A Cochrane Review
por: Rees, Karen, et al.
Publicado: (2020)

Mediterranean Diet for Primary and Secondary Prevention of Cardiovascular Disease and Mortality: An Updated Systematic Review
por: Laffond, Ana, et al.
Publicado: (2023)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Properties of Polyunsaturated Fatty Acids in Primary and Secondary Prevention of Cardiovascular Diseases in the View of Patients (Silesia, Poland)
por: Krupa-Kotara, Karolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hcee8s53jcho0eanc6a5vrnb5n